Healthcare Industry News: blood glucose
News Release - November 29, 2006
RejuvaCell's Breakthrough Stem Cell Therapy Demonstrates Potential to Revolutionize Treatment for Type-2 DiabetesTOKYO and DELHI, INDIA--(Healthcare Sales & Marketing Network)--Nov 29, 2006 -- RejuvaCell Inc., a global leader in adult stem cell therapy for intractable Heart and Vascular diseases, achieves extraordinary advances in the treatment of type-2 diabetes. Over 200 patients treated to date, with 85% of 100 Patients at one year on, maintain significant improvement.
Type-2 diabetes is responsible for 90-95% of diabetes cases and places a severe burden on a country's economic, social, human and healthcare costs. Diabetes kills one person every 10 seconds.
Global annual medical costs associated with Diabetes are estimated to be 215-375 Billion USD, and it has been the quest of governments, institutions, and pharmaceutical companies to cure diabetes.
RejuvaCell's treatment improves production of Endogenous Insulin, increased the levels of "C Peptide," decreased blood glucose levels and glycated hemoglobin levels more than any treatment in existence and with no complications.
RejuvaCell has entered Partnership with Dr. Naresh Trehan in India, considered one of the top cardiac surgeons in the world, with a reputation of excellence in healthcare. Dr. Trehan and his team will begin treatment of Patients in December.
James Ryan, CEO, RejuvaCell, said, "Dr. Trehan is one of the top cardiac surgeons in the world, and has the talent and tools to utilize and further advance cutting edge technology, he is certain to remain in the forefront in Globalized Healthcare."
Dr. Naresh Trehan said, "Application of stem cell technology in the curing of diabetes holds promise and we are excited to work in researching on RejuvaCell technology in India for the benefit of Indian patients."
About Dr. Naresh Trehan: Dr. Trehan is a globally eminent Cardiac Surgeon and a post graduate from New York University. He established Escorts Heart Institute in 1988, a global landmark in cardiac care and a front runner in research, training and education. Currently the Chairman of the CII Healthcare Committee, President of Indian Healthcare Federation, and former President of the International Society for Minimally Invasive Cardiac Surgery. He has over 300 scientific publications to his credit and recipient of various awards including Padma Shri Award in 1999 and Padma Bhushan in 2001.
About Rejuvacell Inc.: is a (JIG, Inc. subsidiary) world-wide leading biotechnology company in cutting-edge proprietary, adult stem cell-based therapies for treatment of heart failure, Angina, myocardium Infarction, coronary artery and ischemic, and peripheral vascular diseases, and Type-2 diabetes.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's reporting.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.